GAO Finds Community Health Centers Are Leaning Toward Managed Care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

WASHINGTON--As more states use prepaid managed care to control costs and improve access for Medicaid patients, the number of participating community health centers continues to grow. The Government Accounting Office (GAO) finds that such financial arrangements are not incompatible with a mission of delivering health care to the medically underserved, but that these institutions face substantial risks and challenges, which require new knowledge, skills, and information systems.

WASHINGTON--As more states use prepaid managed care to controlcosts and improve access for Medicaid patients, the number ofparticipating community health centers continues to grow. TheGovernment Accounting Office (GAO) finds that such financial arrangementsare not incompatible with a mission of delivering health careto the medically underserved, but that these institutions facesubstantial risks and challenges, which require new knowledge,skills, and information systems.

Articles in this issue
New Probe Detects Fusion of bcr/abl
Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pens
Take a Behind the Scenes Look at ODAC
Michigan Cancer System Named for Woman
Panel Favors Approval of Gemzar for Use In Patients With Late Stage Pancreatic Cancer
High-Dose Chemo Patients to Get Stem Cells With the MDR-1 Gene
Report on Minority Health Finds Few Black Oncologists
Where Are We Going and What Questions Do We Need to Ask?
Phase I Trial of Circadian Patterned Infusion of Continuous IL-2 Opens
Hodgkin's Disease Patients Sought for Trial of MoAb
New Health Care Insurance Reform Legislation Introduced in the Senate
FDA Approves Phase II Trials of Agouron's HIV Protease Inhibitor
House committee Recommends Budget Increases for NIH, NCI
Two New Appointees at the NCI
Chemo Plus Transplant Promising For Advanced Hepatocellular Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.